Supporting the “come back”

Cancer patients often delay and even abandon treatment because of devastating side effects.

Adjunctive agents that help relieve the physical and emotional stresses of chemotherapy not only make regimens more palatable but also improve the patient’s quality of life.

Ativan® (lorazepam) Injection can be an important, supportive adjunct.

Clinical studies suggest that Ativan® Injection can play a significant role in enhancing chemotherapy compliance.1-5
Because of Ativan® Injection’s anxiolytic, sedative and amnesic effects, patients are better able to endure the rigors of their chemotherapy courses.

**Ativan® Injection reduces recall of chemotherapy.**

The reduction of recall for the chemotherapy experience is considered by most patients to be not only acceptable but highly desirable.¹–⁵

In fact, many patients actually request subsequent pretreatment with Ativan® Injection and strongly prefer regimens that include it, regardless of incidence or intensity of any emetic episodes.³

The pharmacologic effects of Ativan® Injection require that care be taken on the day of therapy to prevent patients from undertaking any activity requiring their full awareness or coordination.

Please see important information on the following page.
COVER LEGEND

The Ouchterlony plate is one of the more frequently used techniques for the identification of antigens and antibodies, by measurement of diffusion gradients in gel. Among its many applications has been the search for tumor-specific antigens.

The technique was introduced by Orjan Ouchterlony of Sweden, in 1948, initially for the in vitro testing of the toxin-producing capacity of diphtheria bacteria (Acta Pathol. Microbiol. Scand., 25: 186-191, 1948). The technique was proved well suited to the analysis of complex serological systems, including analysis that helped to elucidate the structural heterogeneity of immunoglobulins. Ouchterlony reviewed the history of the developments, which extends back to the late Nineteenth Century (Prog. Allergy, 5: 1-78, 1958).

Orjan Thomas Ouchterlony was born in 1914 in Stockholm and received his medical doctorate from the Karolinska Institute. He worked at the State Bacteriology Laboratory from 1935 to 1952. He was professor of bacteriology at the Medical Faculty of the University of Göteborg from 1952 until his retirement in 1980. He has contributed to field epidemiology of infectious diseases as well as to laboratory research and has worked and lectured in Africa, Europe, and the United States. He is a member of the Swedish Academy of Sciences and the recipient of many honors.

We are indebted to Professor Ouchterlony for the information and illustrations. Pictured are Professor Ouchterlony and an Ouchterlony plate.

M.B.S.
BRL's PDGF is unquestionably the purest available.

- **90% Pure**
  Porcine PDGF is a 38,000-dalton protein that becomes a single 17,000-dalton subunit under reducing conditions. Our PDGF is 90% pure as demonstrated by SDS-PAGE.

- **Free of TGF-β**
  The presence of TGF-β, as measured by a competitive assay using radiolabeled TGF-β, is less than one part in 500.

BRL's pPDGF has high biological activity.

- **Indistinguishable from human PDGF**

- **Minimum of 30,000 units per milligram.**
  One unit of activity in a 96-well culture dish gives 50% maximal stimulation of BALB/c 3T3 cells in a DNA synthesis assay in 200μl of medium containing 0.05% serum.

A limited number of free samples are available. Please call the Tech-Line™ to inquire. For research use only.

---

**J. S. STAUFFER CANCER RESEARCH CHAIR POSITION**
**DEPARTMENT OF PATHOLOGY**
**QUEEN'S UNIVERSITY**
**KINGSTON CANADA**

The Department of Pathology, Queen's University, invites applications for an endowed chair in Cancer Research that has been recently funded by the J.S. Stauffer Foundation.

Applicants must be recognized leaders in their research specialty with proven records of excellence in training graduate and postdoctoral students. The successful candidate will be expected to maintain a competitively active research program in cancer biology, and provide intellectual and administrative leadership in expanding the Cancer Research Division of the Department of Pathology. There are also opportunities for productive interaction with the Ontario Cancer Treatment and Research Foundation, the Clinical Trials Unit of the National Cancer Institute of Canada, and other basic and clinical departments involved in cancer research at Queen’s University.

The successful candidate will hold a tenured academic appointment in the Department of Pathology, Faculty of Medicine. Ample laboratory and office space will be provided in the Cancer Research laboratories situated in the Health Sciences Building which houses most faculty in the basic medical sciences. The salary for the position is negotiable, depending on the qualifications of the applicant. Curriculum Vitae should be sent to: Dr. David M. Roberson, Professor and Head, Department of Pathology, Queen's University, Kingston, Ontario, Canada, K7L 3N6.

Candidates of both sexes are equally encouraged to apply. In accordance with Canadian Immigration requirements, this advertisement is directed particularly to Canadian citizens and permanent residents.